Alexandra Sokolova is an Oncology physician affiliated with Oregon Health & Science University. OpenAlex indexes 85 publications with 897 citations (h-index 14); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3485 S. Bond Ave
Portland, OR 97239
Telephone
503-494-4393Provider last certified this registry record 6 Aug 2021.
Clinical trials
- Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Sponsor: Canadian Cancer Trials Group
- Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
Sponsor: OHSU Knight Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca UK LimitedProgram year20253 payments
- Astellas Pharma Global DevelopmentProgram year20251 payment
- Bayer Healthcare Pharmaceuticals Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
58.9%Cytochrome P450 17A1 Inhibitor31.3%Abiraterone Acetate100%Part D≥35 patientsAndrogen Receptor Inhibitor14.4%Xtandi87%Bicalutamide13%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
20%Corticosteroid16.4%Prednisone100%Part D≥32 patientsPotassium supplement3.6%Potassium Chloride100%Part D<11 patientsSensory organs
8.2%Corticosteroid8.2%Dexamethasone100%Part D≥18 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Brian Druker, MD
Oregon Health & Science University
Kevin Winthrop, MD
Oregon Health & Science University
Richard Maziarz, MD
Oregon Health & Science University
Wayne Clark, MD
Oregon Health & Science University
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”